

# 'Recovery' – towards integration into an Irish community mental health team

John McFarland, Paula Street, Esther Crowe Mullins, Anne Jeffers

*Ir J Psych Med* 2009; 26(4): 197-201

## Abstract

**Objectives:** We aimed to further our understanding of the concept of recovery by analysing comments made in small group discussions that occurred on a planning Away Day held by a community mental health team alongside service users and carers, which had recovery as its theme. The purpose of this was to reshape the structure and workings of the team.

**Method:** Five small groups, of approximately 10 individuals each, comprised of service-users, carers, representatives from voluntary organisations and mental health professionals were asked to discuss three questions related to Recovery.

**Results:** The commentary reflected previous qualitative research on the philosophy of recovery. Issues that were raised included defining wellness as independent to illness, constructive risk taking, the importance of social factors, medication issues and the importance of self-management and optimism. The comments subsequently went on to shape community mental health team service delivery.

**Conclusion:** Discussion and reflection between mental health professionals, service users and carers can lead to a change in attitude and practice in a well-resourced, fully multi-disciplinary community mental health team, within which both the biological and non-biological aspects of mental illness are accepted. The result has been an introduction of service changes which have helped develop a team that is more accessible and increasingly collaborative.

**Key words:** Recovery; Recovery model.

## Introduction

"Recovery is a process; a vision; a belief which infuses a system...which providers can hold with service users... grounded on the idea that people can recover from mental illness and that the service delivery system must be constructed based on this knowledge..." *Anthony 2000*

\***John McFarland**, MB, MRCPsych, Research Registrar in Psychiatry, Department of Psychiatry, Clinical Science Institute, National University of Ireland Galway, Galway, Ireland. Email: john.mcfarland@nuigalway.ie

**Paula Street**, MA, NQSW, Mental Health Social Worker, **Esther Crowe Mullins**, Dip COT, Senior Occupational Therapy Manager, **Anne Jeffers**, MB, MRCPsych, MBA, Consultant Psychiatrist, East Galway Mental Health Services, Loughrea Day Hospital, Barrack Street, Loughrea, Galway, Ireland.

\*Correspondence

SUBMITTED: SEPTEMBER 23, 2008. ACCEPTED: FEBRUARY 10, 2009.

Recovery is not a service offered by mental health professionals and it cannot be clearly defined as a treatment or a model. Over recent years, qualitative research has described recovery as a journey that is affected by a complex array of disparate factors.<sup>1</sup> This provides us with a difficulty in conceptualising recovery – a philosophy that embraces efforts to decrease stigma, counter-discrimination, address poverty, foster self-help, lay out multiple paths to wellness and promote social equality.<sup>1</sup>

In Ireland, over the last five years there has been an increasingly eloquent and vocal critique of current service models from sections of the user movement. A number of reports established by service users suggest that their experiences of Irish mental health services reflect a personally disempowering model which places an overemphasis on medication and tends to be based outside an ethos of hope and recovery.<sup>2-5</sup> The commentary calls for a change in mental healthcare, observing that professionals have the potential to engage with service users in a collaborative manner within the philosophy of recovery.<sup>2-5</sup> This is reflected in The Mental Health Commission discussion document on recovery,<sup>6</sup> and *A Vision for Change*,<sup>7</sup> which includes several themes common to recovery, particularly the section on partnership in care.

## Objective

Consideration of such changes within a system of health care requires a dynamic knowledge of the fundamental needs and sensibilities of the people the system is seeking to serve. Recognition of the gap between what is currently being offered by a system of care and what service users actually want can provide information and direction for change.<sup>6,7</sup>

The primary aim in this paper is to reflect on the needs and judgements of individuals within the local catchment area, with specific reference to brain-storming comments which were made in small discussion groups on an Away Day held by the community mental health team (*see Appendix 1*), alongside service users and carers, which had recovery as its theme (*see Appendix 2*). We relate these comments to our understanding of recovery as described in the evolving literature base and, in doing so, move toward clarifying what we mean when we refer to recovery.

Finally, on a pragmatic level, we show how we have incorporated suggestions made on the day into the day to day workings of the team, with the view that recovery does not only relate to rehabilitation services.<sup>8</sup>

## Method

Five small groups, of approximately 10 individuals each, comprised of service-users, carers, representatives from voluntary organisations and mental health professionals were asked to discuss these three questions:

- What does recovery mean to you?
- What do you see as the challenges to recovery?
- What can be improved to make the service more recovery focused?

Headings reflecting their discussion were then presented to the participants in their entirety. These headings have been used in *Tables* in this paper along with discussion and a review of the relevant previous research on the subject.

## Results

### What does recovery mean to you?

Points offered by small discussion groups fell into three main groups; beliefs about self and recovery, beliefs related to illness and recovery and beliefs related to social functioning and recovery.

#### i) Beliefs about oneself and recovery:

- Self-care • Reclaiming personal power • A state of well-being
- Regaining self esteem • Having hopes and dreams
- Being comfortable with myself and accepted • Fulfilling potential
- Back to a better place • Rejoining of a separated jigsaw
- Living full and satisfying life • Process of change in a person's life
- Positive attitude • Completeness • Meaning in Life
- Content • Having a sense of security

Separate to illness, symptomatology or treatment, a clear focus on regaining a sense of self and empowerment was evident. These comments are reflective of the early literature on recovery with Anthony's assertion in 1993 that "recovery can occur though symptoms recur",<sup>9</sup> and more recently, the suggestion that 'wellness' and 'illness' may be considered independent variables.<sup>10</sup>

Correspondingly, it has been observed that individuals with mental health symptoms often find that they lose their 'selves' inside mental illness. A stage of recovering could be seen as re-conceptualising the illness as part of the self, not a definition of the whole,<sup>11</sup> indeed, it has been found that a correlate of favourable outcome in schizophrenia was the individual's ability to differentiate the self from the diagnosis and the illness experience.<sup>12</sup>

#### ii) Beliefs related to illness and recovery

- Understanding the role of medication • Learn to strengthen the positive role
- Managing symptoms as a little bit of me • Not to be phased by the illness
- Having control – drivers seat • Not being dependent on services
- Understanding illness and coping with stressors
- A process – learn from relapses • Right to make mistakes and learn from them

The views expressed reflect the fact the groups were selected from mental health professionals, carers and service users who were well engaged by the service, and had received considerable education on biological theories of mental illness. They do, however, indicate that a crucial prerequisite for recovery is not merely specialist professional intervention, but for the person to find a way of understanding their experience, therefore establishing a sense of personal value.<sup>13</sup>

Giving individuals a coherent framework in which to conceptualise their problem is an important factor in reducing demoralisation and in inducing hope or the expectation of improvement.<sup>14</sup> (A similar viewpoint has also been used

in making a case for using diagnosis in psychiatry<sup>15</sup>). This particular form of psycho-education also enables individuals to fully participate in treatment partnerships in which they can make autonomous decisions with the subsequent increased personal responsibility for the consequences of these decisions.<sup>16</sup>

This will to take responsibility and the 'right to make mistakes' was apparent in the group discussion, reflecting the concerns that have been voiced relating recovery to risk.<sup>17</sup> However this risk does not necessarily need to be borne by one individual – in current clinical practice often the doctor – Roberts and Wolfson,<sup>10</sup> commented on this "shift from risk avoidance to risk sharing", with the conviction that risk is "inevitable and healthy" and necessary for genuine progress.

Risk avoidance at all cost may cause a rupture in the service provider/user relationship with its own inherent dangers, in relation to disengagement.<sup>17</sup> It is also of note that much can be learned from relapse and indeed this is an important component of the Wellness Recovery Action Plan (WRAP) as seen below.<sup>18</sup>

#### iii) Beliefs related to social functioning and recovery:

- Secure accommodation • Gainful employment
- Journey to function in community where one belongs
- Functioning better day to day • Improved lifestyle and choices
- Feeling part of the wider community • Empowerment
- Support • Belonging

The groups envisaged recovery as a profoundly social process and emphasised both the importance of meaningful adult life roles and that mental health services should have a significant focus on active citizenship.

Employment is known to play a significant role in recovery, particularly in the areas of social, existential and spiritual growth as well as the more obvious financial benefit.<sup>19,20</sup>

Many individuals feel that their job contributes to the definition of who they are, embeds one in a social matrix separate to one's home life,<sup>21</sup> and also facilitates the possibilities of further lifestyle change such as finances for leisure pursuits and housing – access to suitable homes, with all the positive connotations that the word suggests, is of major significance in recovery and is increasingly a factor with the ongoing movement of de-institutionalisation.

### What do you see as the challenges to recovery?


These fell into two categories: concerns related to illness and the service available and concerns about the general public and social disadvantage.

#### i) Concerns about illness and the service:

- The Medical Model • Role of patient • Clarity and therapeutic relationship
- Disempowered staff and clients • Service user not involved in care plan
- Non-compliance • Poor Insight • Lack of evidence base
- Symptoms of illness • Medication • Role clarification/conflict/rivalry
- Lack of counseling • Willingness to listen • Resistance/power

It is apparent that some view the 'medical model' as a barrier to recovery and that the two models "stand in significant tension with each other".<sup>10</sup> While the thrust of evidence-based and biological psychiatry has empowered the professional with invaluable insight into the disease model, in

# Helping your patients make their life feel normal again.



**Cymbalta**<sup>®</sup>  
duloxetine

## In determining remission from depression, patients consider a return to one's usual, normal self as very important.<sup>1</sup>

**CYMBALTA<sup>®</sup> (DULOXETINE) REPUBLIC OF IRELAND ABBREVIATED PRESCRIBING INFORMATION.** Presentation Hard gastro-resistant capsules, 30mg or 60mg of duloxetine. Also contains sucrose. **Uses** Treatment of major depressive episodes. Treatment of generalised anxiety disorder. Treatment of diabetic peripheral neuropathic pain (DPNP) in adults. **Dosage and Administration Major Depressive Episodes** Starting and maintenance dose is 60mg once daily, with or without food. Dosages up to a maximum dose of 120mg per day, administered in evenly divided doses, have been evaluated from a safety perspective in clinical trials. However, there is no clinical evidence suggesting that patients not responding to the initial recommended dose may benefit from dose up-titrations. Therapeutic response is usually seen after 2-4 weeks. After establishing response, it is recommended to continue treatment for several months, in order to avoid relapse. **Generalised Anxiety Disorder** The recommended starting dose in patients with generalised anxiety disorder is 30mg once daily, with or without food. In patients with insufficient response the dose should be increased to 60 mg, which is the usual maintenance dose in most patients. In patients with co-morbid major depressive episodes, the starting and maintenance dose is 60mg once daily. Doses up to 120mg per day have been shown to be efficacious and have been evaluated from a safety perspective in clinical trials. In patients with insufficient response to 60mg, escalation up to 90mg or 120mg may therefore be considered. After consolidation of the response, it is recommended to continue treatment for several months, in order to avoid relapse. Abrupt discontinuation should be avoided. When stopping treatment with Cymbalta the dose should be gradually reduced over at least one to two weeks to reduce the risk of withdrawal reactions. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, continue decreasing the dose, but at a more gradual rate. **Diabetic Peripheral Neuropathic Pain** Starting and maintenance dose is 60mg daily, with or without food. The plasma concentration displays large inter-individual variability. Hence, some patients that respond insufficiently to 60mg may benefit from a higher dose. The medicinal response should be evaluated after 2 months treatment. Additional response after this time is unlikely. The therapeutic benefit should regularly be reassessed. **Contra-indications** Hypersensitivity to any of the components. Combination with MAOIs. Liver disease resulting in hepatic impairment. Use with potent inhibitors of CYP1A2, eg. fluvoxamine, ciprofloxacin, enoxacin. Severe renal impairment (creatinine clearance <30ml/min). Should be used in pregnancy only if the potential benefit justifies the potential risk to the foetus. Breast-feeding is not recommended. Initiation in patients with uncontrolled hypertension that could expose patients to a potential risk of hypertensive crisis. **Precautions** Do not use in children and adolescents under the age of 18. No dosage adjustment is recommended for elderly patients solely on the basis of age. However, as with any medicine, caution should be exercised. Data on the use of Cymbalta in elderly patients with generalised anxiety disorder are limited. Use with caution in patients with a history of mania, bipolar disorder, or seizures. Caution in patients with increased intra-ocular pressure or those at risk of acute narrow-angle glaucoma. Duloxetine has been associated with an increase in blood pressure and clinically significant hypertension in some patients. In patients with known hypertension and/or other cardiac disease, blood pressure monitoring is recommended as appropriate, especially during the first month of treatment. Use with caution in patients whose conditions could be compromised by an increased heart rate or by an increase in blood pressure. For patients who experience a sustained increase in blood pressure while

receiving duloxetine, consider either dose reduction or gradual discontinuation. Caution in patients taking anticoagulants or products known to affect platelet function, and those with bleeding tendencies. Hyponatraemia has been reported rarely, predominantly in the elderly. Caution is required in patients at increased risk for hyponatraemia, such as elderly, cirrhotic, or dehydrated patients, or patients treated with diuretics. Hyponatraemia may be due to a syndrome of inappropriate anti-diuretic hormone secretion (SIADH). It is general clinical experience that the risk of suicide may increase in the early stages of recovery from depression. Other psychiatric conditions for which Cymbalta is prescribed can also be associated with an increased risk of suicide-related events. Patients with a history of suicide-related events or those exhibiting a significant degree of suicidal thoughts prior to commencement of treatment are known to be at greater risk of suicidal thoughts or suicidal behaviour, and should receive careful monitoring during treatment. A meta-analysis of placebo-controlled clinical trials of antidepressant drugs in psychiatric disorders showed an increased risk of suicidal behaviour with antidepressants compared to placebo in patients less than 25 years old. Close supervision of patients, and in particular those at high risk, should accompany drug therapy, especially in early treatment and following dose changes. Patients (and caregivers of patients) should be alerted about the need to monitor for any clinical worsening, suicidal behaviour or thoughts, and unusual changes in behaviour, and to seek medical advice immediately if these symptoms present. Since treatment may be associated with sedation and dizziness, patients should be cautioned about their ability to drive a car or operate hazardous machinery. Cases of akathisia/psychomotor restlessness have been reported for duloxetine. In patients who develop these symptoms, increasing the dose may be detrimental. Duloxetine is used under different trademarks in several indications (major depressive episodes, generalised anxiety disorder, stress urinary incontinence, and diabetic neuropathic pain). The use of more than one of these products concomitantly should be avoided. Cases of liver injury, including severe elevations of liver enzymes (>10-times upper limit of normal), hepatitis, and jaundice have been reported with duloxetine. Most of them occurred during the first months of treatment. Duloxetine should be used with caution in patients with substantial alcohol use or with other drugs associated with hepatic injury. **Interactions** Caution is advised when taken in combination with other centrally acting medicinal products and substances, including alcohol and sedative medicinal products; exercise caution when using in combination with antidepressants. In rare cases, serotonin syndrome has been reported in patients using SSRIs concomitantly with serotonergic products. Caution is advisable if duloxetine is used concomitantly with serotonergic antidepressants like SSRIs, tricyclics, St John's Wort, venlafaxine, or triptans, tramadol, pethidine, and tryptophan. Undesirable effects may be more common during use with herbal preparations containing St John's Wort. **Effects on other drugs:** Caution is advised if co-administered with products that are predominantly metabolised by CYP2D6 (risperidone, tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine) particularly if they have a narrow therapeutic index (such as fentanyl, propofene, and metoprolol). **Anticoagulants and antiplatelet agents:** Caution should be exercised when duloxetine is combined with oral anticoagulants or antiplatelet agents due to a potential increased risk of bleeding. Increases in INR values have been reported when duloxetine was co-administered with warfarin. **Undesirable Effects** The majority of common adverse reactions were mild to moderate, usually starting early in therapy, and most tended to subside as therapy continued. Those observed from spontaneous reporting and in placebo-controlled

clinical trials in depression, generalised anxiety disorder, and diabetic neuropathic pain at a rate of  $\geq 1/100$ , or where the event is clinically relevant, are: *Very common* ( $\geq 1/10$ ): Headache, somnolence, dizziness, nausea, dry mouth. *Common* ( $\geq 1/100$  and  $< 1/10$ ): Weight decrease, palpitations, tremor, paraesthesia, blurred vision, tinnitus, constipation, diarrhoea, vomiting, dyspepsia, flatulence, sweating increased, musculoskeletal pain, muscle tightness, muscle spasm, decreased appetite, flushing, fatigue, abdominal pain, erectile dysfunction, insomnia, agitation, libido decreased, anxiety, orgasm abnormal, abnormal dreams. *Clinical trial and spontaneous reports of anaphylactic reaction, hyperglycaemia* (reported especially in diabetic patients), mania, hyponatraemia, SIADH, hallucinations, dyskinesia, serotonin syndrome, extra-pyramidal symptoms, convulsions, akathisia, psychomotor restlessness, glaucoma, mydriasis, syncope, tachycardia, supra-ventricular arrhythmia (mainly atrial fibrillation), syncope, hypertension, hypertensive crisis, epistaxis, gastritis, haematochezia, dysuria, gastrointestinal haemorrhage, hepatic failure, hepatitis, acute liver injury, angioneurotic oedema, Stevens-Johnson syndrome, Trismus, and gynaecological haemorrhage have been made. Cases of suicidal ideation and suicidal behaviours have been reported during duloxetine therapy or early after treatment discontinuation. Cases of aggression and anger have been reported, particularly early in treatment or after treatment discontinuation. Cases of convulsion and tinnitus have been reported after treatment discontinuation. Discontinuation of duloxetine (particularly abrupt) commonly leads to withdrawal symptoms. Dizziness, sensory disturbances (including paraesthesia), sleep disturbances (including insomnia and intense dreams), fatigue, agitation or anxiety, nausea and/or vomiting, tremor, headache, irritability, diarrhoea, hyperhidrosis, and vertigo are the most commonly reported reactions. The heart rate-corrected QT interval in duloxetine-treated patients did not differ from that seen in placebo-treated patients. No clinically significant differences were observed for QT, PR, QRS, or QTcB measurements between duloxetine-treated and placebo-treated patients. In clinical trials in patients with DPNP, small but statistically significant increases in fasting blood glucose were observed in duloxetine-treated patients compared to placebo at 12 weeks. At 52 weeks there was a small increase in fasting blood glucose and in total cholesterol in duloxetine-treated patients compared with a slight decrease in the routine care group. There was also an increase in HbA1c in both groups, but the mean increase was 0.3% greater in the duloxetine-treated group. *For full details of these and other side-effects, please see the Summary of Product Characteristics, which is available at <http://www.medicines.ie/>* **Overdose** Cases of overdoses, alone or in combination with other drugs, with duloxetine doses of 5400mg were reported. Some fatalities have occurred, primarily with mixed overdoses, but also with duloxetine alone at a dose of approximately 1000mg. Signs and symptoms of overdose (duloxetine alone or with mixed medicinal products) included somnolence, coma, serotonin syndrome, seizures, vomiting, and tachycardia. **Legal Category** POM. **Marketing Authorisation Numbers and Holder** EU/1/04/296/001, EU/11/04/296/002, Eli Lilly Nederland BV, Grootslag 1-5NL-3991 RA Houten, The Netherlands. **Date of Preparation or Last Review** March 2009. **Full Prescribing Information is Available From** Eli Lilly and Company Limited, Lilly House, Priestley Road Basingstoke, Hampshire, RG24 9NL. Telephone: Basingstoke (01256) 315 999 or Eli Lilly and Company (Ireland) Limited, Hyde House, 65 Adelaide Road, Dublin 2, Republic of Ireland. Telephone: Dublin (01) 661 4377. **CYMBALTA** (duloxetine) is a trademark of Eli Lilly and Company. **Date of Preparation:** April 2009. **Reference:** 1. Zimmerman M, McGlinchey JB, et al. *Am J Psychiatry* 2006;163:148-150.

IECYM00016



our discussion it was suggested that the manner in which this knowledge is delivered is partially inadequate to meet the needs of the service user.

Recovery is seen as different to a biopsychosocial model. In the ethos of recovery, the service-user is seen as both active and responsible,<sup>18</sup> working with and alongside the professional. Commentary has suggested that a different use of language is required to reflect this and also to emphasise this collaborative approach.<sup>23</sup>

The use of the term 'patient' has been criticised by individuals who have taken exception to its inherently passive connotations (waiting to be 'treated'), with preference given to other terms, such as consumer or service-user – terms that may offer identities that enable people to reclaim some sense of responsibility for their situations. We are aware that this is not a universal opinion and has been the topic of recent debate.<sup>24</sup>

It was clear that for some the experience of taking medication, side-effects, lack of pharmaco-education and the fundamental implication of taking medication for what they may see as 'emotional' problems can actually be a more distressing experience than that of the disorder itself.<sup>25</sup>

From our discussions it was agreed that doctors should discuss both the benefits that medications offer and their limitations,<sup>26</sup> while also remaining aware of the fact that some patients may improve and remain improved without the use of prescribed drugs.<sup>25</sup>

The commentary from the groups is not, in our opinion, indicative of anti-psychiatry rhetoric (and, indeed, we accept the biological nature of mental illness), and does not equate with an abandonment of what medicine has to offer in terms of managing symptoms and illness, but is representative of a process of reclaiming the whole person from the partiality of a purely medical definition.

#### ii) Concerns about the general public and social disadvantage:

- Lack of education • Public attitude, stigma • Lack of meaningful work
- Culture and environment • Ignorance
- Fear of stigma, relapse and the unknown
- Tradition • Everyday stressors • Fears and anxieties from all bodies
- Stigma • Celtic Tiger

Further discussion focussed on the areas of stigma and social exclusion. Stigma has been referred to as the most formidable obstacle to future progress in the arena of mental health,<sup>26</sup> and there is compelling evidence to reinforce the detrimental effects that the groups referred to.

As alluded to earlier in this article it has been found that stigma was an independent and significant predictor of self esteem. This may suggest that reducing social stigma may help reduce the internalised stigma that restricts the ability of some service users to define 'a self' apart from their diagnosis.<sup>11</sup>

Socially, there are high rates of parents with severe mental illness losing custody of their children, of unemployment amongst those with severe mental illness and in the number of people who spend their lives in segregated settings rather than as integrated community members.<sup>27</sup>

Further, higher levels of perceived stigma at the start of antidepressant treatment predict poorer compliance with medication,<sup>28</sup> and it has also been found that concerns about

stigma during an acute phase of illness in individuals with bipolar disorder are significantly associated with poorer social adjustment seven months later.<sup>29</sup>

Prejudice, ignorance and discrimination have been identified as the three components of stigma which need to be addressed,<sup>30</sup> and we will allude to these later in this paper.

### What can be improved to make the service more recovery focused?

As can be seen in the group discussions, service-users, because of their experiences, bring different attitudes, motivations and insights to mental health treatment. These important perspectives display the need for their direct participation in treatment planning, evaluation and research activities in creating a system that focuses on recovery.<sup>1</sup> The following comments, made at the end of day summary, have particularly shaped our current practice.

#### i) Developing self-management plans:

- Allowing patient to make decisions for themselves
- Identify strengths and abilities • Self help groups
- Partnership – working with client • More input from patient in their care
- Autonomy • Learn from positive achievements

#### (i) Developing self management plans

Both professionals and service-users were vocal on the importance of self-management. Studies show that self-management, or a person's determination to get better, manage the illness, take action, face problems, and make choices, can facilitate recovery from mental illnesses.<sup>1</sup>

It was thought that an area of focus should be on programmes that develop the confidence and motivation of patients with ongoing symptoms to use their own resources and strengths to take control of their lives. At initial contact individuals who present to the service are assisted in developing an understanding of the origins of their distress using the Stress Vulnerability Model,<sup>31</sup> and following the Away Day the service has been in the process of introducing the Wellness Recovery Action Plan (WRAP),<sup>32</sup> developed by Mary Ellen Copeland and extensively explained on her website, videos and workbooks.

It describes how individuals can facilitate their own wellness by developing a daily maintenance plan, identifying triggers to relapse and formulating an action plan for use when they identify early warning signs of relapse. WRAP also encourages development of a crisis plan, which may allow an individual to keep control in times of crisis, as well as a post-crisis plan, which enables professionals and service users to reflect on how a crisis was managed. Empirical research is possible with WRAP due to the availability of a pre-test post-test instrument developed by the model's creator and there is an evolving evidence base for its use.<sup>33</sup> Using DVDs and workbooks we have introduced WRAP in both individual and group formats. Service users have identified these groups as particularly empowering and professionals have identified them as a powerful tool for collaborative working.

#### ii) Outpatients and care-coordination:

- NCHD rotation • Lack of choice • Partnership – working with client
- Choice of doctor • Work as MDT

**(ii) Outpatients and care co-ordination**

Qualitative research within the catchment-area has demonstrated dissatisfaction with outpatient clinics,<sup>9</sup> and this was again apparent in the group discussions. Service-users have raised the issue of frequent NCHD rotation and their perception that doctors focus overtly on symptoms of illness to the exclusion of other aspects of an individual's life.

We have incorporated good practice guidelines which identify that all individuals referred to a mental health service should have a comprehensive assessment addressing medical, psychological, occupational, economic and social needs<sup>26</sup> with ongoing work alongside the member of the team who is considered the most appropriate care coordinator. Along with liaising with the consultant, GP, family members and with other members of the team, the care-coordinator may assist individuals in linking in with main stream work and training within the community – this is facilitated by strengths-based recovery care plans which have been developed by the team.

The system borrows from the business world by using a 'pull' system for review at outpatient clinics, where individuals are seen by doctors in time and when required, rather than the inefficient 'push' system of traditional outpatient clinics and this is in keeping with the view that psychiatrists should be "on tap and not on top."<sup>34</sup>

Service users are facilitated with earlier discharge from the service with an agreement that should they require future input they can re-refer themselves directly to a mental health professional who knows them thus gaining a sense of control of their management and using the service as a "springy safety net".<sup>10</sup>

It was apparent in discussion that individuals want a service that they can contact when they need it, without necessarily becoming occupied with long term involvement and monitoring, however well intentioned. The use of educational and recovery groups help ensure service users are making informed decisions.

**iii) Focus on stigma and social inclusion:**

- Believing in people
- Allowing patients to make decisions for themselves
- Education

**(iii) Focus on stigma and social inclusion**

Research suggests that stigma should be tackled with a three-pronged approach, at personal, local and then national levels.<sup>35</sup> It was observed that any fundamental change in the dichotomous 'us and them' thinking that underlies stigmatisation must start with the shift in the interpersonal dynamic in relationships between service-users and the professionals that treat them, reflecting the evidence that viewing a mental health professional as an experienced and committed person who believes in you and your future has a major impact on outcome.<sup>36</sup>

As recommended by the WHO, well-planned public awareness and education campaigns which may reduce stigma and discrimination, increase the use of mental health services, and bring mental and physical health care closer to each other have been discussed with view to implementation.<sup>37</sup>

The importance of work and employment in recovery has led to a focus within the team in supporting individuals to

returning to work and training. While acknowledging the role of stress in relapse, the benefits of work are emphasised and all efforts are made to support employers and employees.

**iv) Reflective practice:**

- Balance between care giving and letting go
- Identify strengths and abilities
- Learn from positive achievements
- Working as a multi-disciplinary team
- Empowerment
- Reflective practice
- Encouraging

**(iv) Reflective practice**

Within the team there has been a marked change in communication since the integration of the values of recovery, with roles clearly defined and a distinct respect for the views of all, particularly the service user. We have endeavoured to provide a team environment where there is a culture of realistic respect, collaboration and trust within which decisions are robustly reviewed and clinical concerns are openly discussed in a group setting.

Where an individual makes a request that professionals feel may not be in their best interest, significantly more time is put into engaging, empowering and supporting the individual to make a well informed choice, and the service supports the individual in the consequences of that choice. Regular communication and an awareness of risk, ensures this is carried out safely.

On the occasions where individuals are detained under the Mental Health Act, in keeping with recent recommendations,<sup>38</sup> ongoing reflection and discussion during and after hospitalisation is used to inform further management.

**v) Hope and optimism:**

- Carrying/inspiring hope
- Believing in people
- Encouraging
- Have belief and confidence in client
- Having dreams and hopes
- Instilling hope
- Positive attitude

**(v) Hope and optimism**

Finally, and most importantly, for the service user, being met with hope and optimism, especially at initial contact is of central significance.

In our practice we hope to keep in mind the dimensions of "hope inspiring relationships",<sup>20</sup> valuing people as individuals, accepting and understanding, believing in their abilities and potential and accepting failures and setbacks as part of the recovery process.

**Limitations of design**

The groups were comprised of service-users and staff, the majority of whom had received considerable education around the biological nature of mental illness and, as such, they may not have been an entirely representative sample. Conversely previous recovery research has been open to the criticism of over-representing those with an anti-psychiatry viewpoint. This is an ongoing issue and despite the mounting qualitative research that emphasises the importance of hope, autonomy, self determination and patient-participation, evidence for recovery-based approaches, in the form of well-controlled, representative and quantitative study, is not well developed.<sup>39</sup>

**Conclusions**

This paper has described how an annual sector planning

day was used to facilitate greater emphasis on recovery principles within a community mental health team.

In Ireland, there may be a perception that recovery and wellness is, at best, the remit of rehabilitation psychiatry and, at worst, an incorporation of areas of anti-psychiatry. This paper shows how discussion and reflection between mental health professionals, service users and carers can lead to a change in attitude and practice in a well-resourced, fully multi-disciplinary community mental health team, within which both the biological and non-biological aspects of mental illness are accepted.

The result has been an introduction of service changes which have helped develop a team that is more accessible and increasingly collaborative. Ideas borrowed from areas such as *New Ways of Working*,<sup>40</sup> have proved useful in aiding the introduction of these services.

### Acknowledgements

We wish to extend our thanks to the Loughrea Atherny Community Mental Health Team, service users and carers, John Saunders, Schizophrenia Ireland; Jutta Kirrkamm, Irish Advocacy Network; and Liz Brosnan, Western Mental Health Alliance for participation on the planning day and Professor Colm McDonald for editorial assistance.

Declaration of Interest: None.

### References:

- Allott P, Loganathan L, Fulford KWM. Discovering hope for Recovery. *Can J Comm Ment Health* 2002; 21:13-33.
- Mental Health Commission. A Vision for a Recovery Model in Irish Mental Health Services: Discussion Paper. Mental Health Commission, 2005.
- Brosnan L, Collins S, Dempsey H, Maguire L, Morrin, N. The Pathways Report; Experiences of Mental Health Services from a User-led Perspective. Western Health Board and Schizophrenia Ireland, 2002.
- Schizophrenia Ireland/Irish Psychiatric Association. Towards Recovery. Dublin 2002.
- Department of Health and Children, Expert Group on Mental Health Policy. What We Heard; Consultation Paper. Department of Health and Children, 2004.
- Mental Health Commission. A Vision for a Recovery Model in Irish Mental Health Services: Discussion Paper. Mental Health Commission, 2005.
- Expert Group on Mental Health Policy. A Vision for Change. Dublin: The Stationary Office, 2006.
- Irish College of Psychiatrists. How to set up rehabilitation and recovery services in Ireland. Occasional Paper. Irish College of Psychiatrists, 2007.
- Anthony WA. Recovery from Mental Illness: The guiding vision of the Mental Health service system in the 1990s. *Psychosoc Rehabil J* 1993; 16: 11-23.
- Roberts G, Wolfson P. The Rediscovery of Recovery: Open to All. *APT* 2004; 10: 37-49.
- Jacobson N, Greenley D. What is Recovery? A Conceptual Model and Explication. *Psychiatr Serv* 2001; 52: 482-85.
- Davidson L, Strauss JS. Beyond the Biopsychosocial model: Integrating Disorder, Health, and Recovery. *Psychiatry* 1995; 58: 44-55.
- Frank JD. *Persuasion and Healing*. (2nd Ed) New York: Schocken, 1973.
- Feltham I. *Controversies in Psychotherapy and Counseling*. Sage Publications 1999.
- Deegan E. Recovery: The lived experience of Rehabilitation. *Psychosoc Rehabil J* 1998; 11: 11-19.
- Mueser KT, Corrigan P, Hilton T et al. Illness Management and Recovery: A Review of the Research. *Focus* 2004; 2: 34-47.
- Fisher DB. Healthcare reform based on an empowerment model of recovery by people with psychiatric disabilities. *Hosp Community Psychiatry* 1994; 45: 913-5.
- Copeland ME. WRAP – Wellness Action Recovery Plan. Peach Press, 1997.
- Leff J, Thornicroft G, Coxhead N, Crawford C. The TAPS Project. 22: A Five-Year follow-up of Long-Stay Psychiatric patients discharged to the Community. *Br J Psychiatry Suppl*. 1994; 25: 13-7.
- Repper J, Perkins R. *Social Inclusion and Recovery*. London: Baillière Tindall, 2003.
- Roberts G, Davenport S, Holloway F, Tattan T (eds). *Enabling Recovery. The Principles and Practice of Rehabilitation Psychiatry*. Gaskell, 2006.
- Department of Health. *The Expert Patient: A New Approach to Chronic Disease Management for the 21st Century*. London: Department of Health, 2001.

- McLaughlin H. What's in a Name: 'Client', 'Patient', 'Customer', 'Consumer', 'and Expert by Experience', 'Service User' – What's Next? *Br J Soc Work* 2008; 10: 1-17.
- Craddock N, Antebi D, Attenburrow MJ et al. Wake-up call for British Psychiatry. *Br J Psychiatry* 2008; 193: 6-9.
- Lynch T. *Beyond Prozac: Healing Mental Suffering without Drugs*. Marino Books, 2001.
- National Institute for Clinical Excellence. *Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care*. Clinical Guideline 1. London: NICE 2002.
- Corrigan PW. Target-specific Stigma change: A Strategy for Impacting Mental Illness Stigma. *Psych Rehab* 2004; 28: 113-21.
- Link BG, Struening EL, Neese-Todd S, Asmussen S, Phelan JC. The Consequences of Stigma for the self-esteem of people with Mental Illnesses. *Psychiatr Serv* 2001; 52: 1621-6.
- Sirey JA, Bruce ML, Alexopoulos GS, Perlick DA, Friedman SJ, Meyers BS. Perceived Stigma and Patient-Rated Severity of Illness as Predictors of Antidepressant Drug Adherence. *Psychiatr Serv* 2001; 52: 1615-20.
- Thornicroft G, Rose D, Sartorius N. Stigma: Ignorance, Prejudice or Discrimination? *Br J Psychiatry* 2007; 190: 192-3.
- Zubin J, Spring B. 1977 Vulnerability; a new view of Schizophrenia. *J Abnorm Psychol* 1977; 86: 103-26.
- maryellencopeland.com
- Copeland ME. Overview of WRAP: Wellness Recovery Action Plan. *Mental Health Recovery Newsletter* 2002; 3: 1-9.
- Deegan G. *Discovering Recovery*. *Psych Rehab* 2003; 26: 368-76.
- Thornicroft G. *Shunned*. Oxford University Press 2006.
- Ramsay R, Page A, Goodman T et al. *Changing Minds: Our Lives and Mental Illness*. London: Gaskell 2002.
- World Health Organisation. [www.euro.who.int/mentalhealth/topics/20061129\\_3](http://www.euro.who.int/mentalhealth/topics/20061129_3)
- Roberts G, Dorkins E, Wooldridge J, Hewis E. Detained – what's my choice? Part 1: Discussion. *APT* 2008; 12: 172-180.
- Oades L, Deane F, Crowe T, Lambert W, Kavanagh D, Lloyd C. Collaborative Recovery. An integrative Model for working with Individuals who experience chronic and recurring Mental Illness. *Australas Psychiatry* 2005; 13: 279-84.
- Royal College of Psychiatrists and National Institute for Mental Health in England. *New Ways of Working for Psychiatrists: Enhancing Effective, Person-centered Services through New Ways of Working in Multidisciplinary and Multi-agency Contexts*. Final Report 'But Not the End of the Story'. London: Department of Health, 2005.

### Appendix 1: Description of the Service

The Loughrea-Atherny Community Mental Health Team is a well resourced community mental health team, with a complete multidisciplinary team. Monthly service development meetings are held, which are attended by service user representatives. The team receives ongoing feedback from service users and carers on the Service. A team training day is held annually and is attended by service users and carers. The entire team meets with GPs in the area on an annual basis.

### Appendix 2: Description of the Day

The proposal to base the Annual Away Day for the Loughrea/Atherny Mental Health Service on the concept of 'Recovery in Mental Health' was decided at a team sector development meeting following a presentation by the team's social worker on recovery.

Planning was carried out by the team's occupational therapist and social worker with an extensive literature review on the concept of recovery and through contact with voluntary sector organisations focused on recovery. Representatives from voluntary sector organisations were invited to attend the day. These included Schizophrenia Ireland, Western Alliance for Mental Health and the Irish Advocacy Network.

The Annual Away Day has been running for 10 years and its attendees have included multi disciplinary team members from both the inpatient facilities and those within the community based team. Service users and carers were invited to attend the day in keeping with recovery principles, ensuring that service users' and carers' voices are heard.